Purpose To compare the embryo outcomes of in vitro fertilization/intra-cytoplasmic sperm injection with a gonadotropin-releasing hormone (GnRH) antagonist protocol with follicle stimulating hormone (FSH) and with human menopausal gonadotropin (hMG). Methods We performed a retrospective cohort study in 465 patients. Stimulation was started by daily FSH injection, and either FSH was continued (FSH alone group) or hMG was administrated (FSH-hMG group) after administration of a GnRH antagonist. Primary outcomes were the embryo profile (number of retrieved, mature, and fertilized eggs, and morphologically good embryos on day 3) and endocrine profile. Secondary outcomes were the doses and durations of gonadotropin. Data were stratified by the patients' age into two groups: \35 years and C35 years. Results In patients aged \35 years, the number of retrieved oocytes in the FSH alone group was significantly increased than that in the FSH-hMG group (13.7 vs 9.2, P = 0.04), while there was no difference at other age groups. The FSH-hMG group required a significantly greater amount of gonadotropins at any age (all ages, P \ 0.001; \35 years, P = 0.013; C35 years, P \ 0.001). Conclusions Exogenous FSH alone is probably sufficient for follicular development and hMG may not improve the embryo profile in a GnRH antagonist protocol across all age.
Introduction
In controlled ovarian stimulation (COS) of assisted reproductive technology (ART), FSH is essential but significance of luteinizing hormone (LH) supplementation is controversial. Recent meta-analyses have shown that human menopausal gonadotropin (hMG) leads to higher pregnancy rates than recombinant follicle stimulating hormone (rFSH) in a long gonadotropin-releasing hormone (GnRH) agonist protocol [1] [2] [3] . The GnRH antagonist protocol is widely used, as well as the GnRH agonist protocol for COS for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). However, whether supplementation of LH is beneficial in this protocol is unclear. A few randomized controlled trials (RCT) reported that highly purified hMG (hp-hMG) and rFSH showed similar outcomes, such as the pregnancy rate, the pregnancy loss rate, and the live birth rate [4, 5] .
In contrast, the inhibitory effect of GnRH antagonists on LH secretion and a lower pregnancy rate has been shown in a dose-dependent manner (Ganirelix Dose-finding Study Group, 1998 [6] ). Endogenous LH levels may fall too low, particularly in advanced reproductive age women, indicating that the effect of LH supplementation in the GnRH antagonist protocol in older women is debatable. Consequently, the optimal ovarian stimulation protocol according to age needs to be established.
In this study, we aimed to examine the IVF/ICSI outcome in a GnRH antagonist protocol with FSH or hMG among all ages, including older reproductive age. We conducted a retrospective analysis on the embryo and endocrine profiles. Data were stratified by the patients' age into two groups: \35 years and C35 years. In the FSH alone group (313 patients), 49 patients were \35 years and 264 were C35 years. In the FSH-hMG group (152 patients), 23 patients were \35 years and 129 were C35 years.
Trial end points
Primary outcomes were the number of retrieved oocytes, mature oocytes, normally fertilized (2PN) eggs, and morphologically good embryos on day 3 (D3 good-quality embryos), and hormone levels. Secondary outcomes were the amount of gonadotropin used and the duration of treatment.
Statistical analysis
Data are expressed as the mean ± SD for continuous variables. Normality of distribution of continuous variables was assessed with the Kolmogorov-Smirnov test.
Differences between groups of normally distributed variables (hormone levels) were assessed with the Student's t test, while non-normally distributed variables were evaluated with a non-parametric test (Mann-Whitney test). A P value \0.05 was considered significant. This study was approved by the institutional review board of our hospital.
Results

Baseline characteristics
Baseline characteristics of the study participants are shown in Table 1 . The patients' characteristics were similar between the FSH alone group and the FSH-hMG group in each age group, as well as basal hormone levels and antral follicle count.
Endocrine profile
In every age group (total, \35 years, C35 years), serum estrogen, LH and progesterone levels on the day of trigger administration were similar between the FSH alone group and the FSH-hMG groups (Table 2 ).
Egg and embryo profile
In patients aged\35 years, the number of retrieved oocytes in the FSH alone group was significantly increased than that in the FSH-hMG group (13.7 ± 10.2 vs 9.2 ± 4.2, P = 0.04). The number of mature oocytes, the number of fertilized eggs, fertilization rate, and the number of D3 good-quality embryos were similar between the two groups. No differences were observed between the FSH alone group and the FSH-hMG group in patients aged C35 years and in total group (Table 3) .
Amount of gonadotropin
In patients of every age group, the amount of gonadotropin after starting GnRH antagonists increased in the FSH-hMG group compared with the FSH alone group. This resulted in a significantly higher amount of total gonadotropin administered in the FSH-hMG group though the amount of gonadotropin before a GnRH antagonist using was not different between the two groups. The duration of gonadotropin treatment was similar between the FSH alone and the FSH-hMG groups across all age groups (Table 4) .
Logistic regression analysis revealed no correlation between hMG addition and the good embryo outcome, such as nine or more retrieved oocytes (odds ratio (OR):0.76, 95 % confidence interval (CI) 0.48-1.21) and The hormone levels were similar between the two groups in every age group
Values are expressed as mean ± SD. P \ 0.05 is considered as statistically significant E2 estrogen, P progesterone seven or more mature oocytes (OR: 0.75, 95 % CI 0.51-1.11).
Discussion
This retrospective study showed that administration of hMG in the late follicular phase did not improve the embryo outcome in the GnRH antagonist protocol regardless of age. In addition, our study showed that there were no differences in serum LH, estrogen and progesterone levels with or without hMG administration. Previous studies comparing FSH and hMG/FSH ? rLH in a GnRH antagonist protocol [4, 5, [7] [8] [9] [10] [11] are varied in terms of the type of intended patients, the timing for hMG administration, and the type of gonadotropins. Most studies analyzed relatively young women with regard to reproductive age (i.e., women \40 years old with a mean age of 30-33 years). However, currently, women's age for ART treatment is getting older. In fact, the mean age for ART exceeded 35 years old since 2011 in the United States, and more than half of infertile women in United States and Europe are older than 35 years [12, 13] . Therefore, studies need to be performed in women 40 years or above although there are only a few. Chung et al. [14] performed a retrospective study in 141 cases stratified by an age of \40 years and [40 years. In addition, König et al. [15] conducted a randomized controlled trial in 253 patients only aged [35 years on LH supplementation. Our study was retrospective but included larger numbers of patients (465 patients) with mean age 38.8 years (29-45 years), which consisted of 72 patients (15 %) in \35 years old and 393 patients (85 %) in C35 years old. No difference in the embryo and endocrine profile between continuance of rFSH/uFSH and administration of hMG was observed (e.g. the number of retrieved oocytes in total age group, 9.6 ± 6.7 vs 8.5 ± 5.5, N.S.), and it is consistent with those two studies [14, 15] .
Our study was designed to compare FSH and hMG in the late follicular phase, whereas some studies started hMG/rLH from the beginning of stimulation [4, 5, 11] . Despite of the timing of starting LH supplementation, hMG/rLH did not improve the embryo profile and increased the amounts of gonadotropins.
With regard to the type and dose of gonadotropin used, the FSH alone group involved both rFSH and uFSH, and hMG contained hp-hMG, not rLH or recombinant hCG. Therefore, quantifying the precise biological activity of gonadotropins was difficult. However, Requena [16] reported that endocrine and follicular profiles were not different between rFSH ? rLH and hp-hMG stimulation and previous studies also compared hMG with uFSH [5, 11, 14, 16] .
Regardless of these limitations of our study, this is the largest and most practical trial, which included women aged C35 years, and hMG was added after a GnRH antagonist.
Furthermore, our evaluation focused on the embryo profile. Most studies investigated the pregnancy or the delivery rate, but those outcomes are affected with a lot of factors, not only quality of embryo, but also number of embryo transferred, local hormone levels, uterine receptivity, and other maternal complications. On the other hand, quality of oocytes and embryos is one of the most relevant factors determining the success of IVF treatment. Among several factors affecting quality of embryos, an ovarian stimulation protocol is eligible and adjustable.
In conclusion, exogenous rFSH/uFSH alone is probably sufficient in the GnRH antagonist protocol for optimal ovarian stimulation to achieve morphologically good embryos across all ages. Moreover, hMG was not beneficial in advanced reproductive age and rFSH/uFSH increased the number of retrieved eggs and subsequently may lead to better embryos in younger normo-gonadotropic patients. After GnRH ant. (days) 3.6 ± 0.9 3.8 ± 0.9 NS 3.6 ± 0.8 3.6 ± 0.8 NS 3.6 ± 0.9 3.6 ± 0.8 NS Total (IU) 1686 ± 590 2038 ± 555 0.013 2050 ± 591 2272 ± 542 \0.001 2012 ± 614 2244 ± 555 \0.001
Total (days) 9.2 ± 1.4 9.8 ± 1.6 NS 9.1 ± 1.5 9.0 ± 1.3 NS 9.1 ± 1.5 9.1 ± 1.5 NS
The total amount of gonadotropin and that after starting GnRH antagonists increased in the FSH-hMG group compared with the FSH alone group in every age group
Values are expressed as mean ± SD. P \ 0.05 is considered as statistically significant
GnRH ant., GnRH antagonist
